TABLE 1.

Characteristics of VWF in NSR controls and NVAF cases

Variable	Controls NSR (N = 100)	Overall NVAF (N = 425)	P	Duration of atrial fibrillation
				<1 mo (N = 76)	1–12 mo (N = 98)	>12 mo (N = 251)	P
Age, y (mean ± SD)	63.4 ± 14	62.6 ± 13	.5865	63.1 ± 15	61.8 ± 13	62.7 ± 12	.76
<65, n (%)	51 (51%)	242 (57%)	.2818	41 (54%)	52 (53%)	149 (59%)	.48
65–74 y, n (%)	24 (24%)	109 (26%)	.7333	16 (21%)	35 (36%)	58 (23%)	.032
≥75, n (%)	25 (25%)	74 (17%)	.0809	19 (19%)	11 (11%)	44 (18%)	.059
Female, n (%)	39 (39%)	104 (25%)	.0033	11 (15%)	19 (19%)	74 (29%)	.012
Congestive heart failure, n (%)	15 (15%)	100 (24%)	.0635	24 (32%)	27 (28%)	49 (20%)	.053
Hypertension, n (%)	50 (50%)	253 (60%)	.0826	44 (58%)	58 (59%)	151 (60%)	.94
Diabetes mellitus, n (%)	21 (21%)	58 (14%)	.0643	6 (8%)	18 (18%)	34 (14%)	.14
Stroke/TIA prior, n (%)	6 (6%)	59 (14%)	.0313	7 (9%)	10 (10%)	42 (17%)	.12
Antiplatelet therapy, n (%)	51 (51%)	203 (48%)	.5602	32 (42%)	45 (46%)	126 (50%)	.43
Warfarin therapy, n (%)	2 (2%)	327 (77%)	<.0001	56 (74%)	86 (88%)	185 (74%)	.015
Statin therapy, n (%)	35 (35%)	159 (37%)	.6530	22 (29%)	36 (37%)	101 (40%)	.20
CHADS2, n (%)
mean ± SD	1.23 ± 1.3	1.42 ± 1.4	.2086	1.41 ± 1.2	1.36 ± 1.3	1.44 ± 1.4	.90
0	36 (36%)	129 (30%)	.3212	22 (29%)	30 (31%)	77 (31%)	.93
1	33 (33%)	131 (31%)		21 (28%)	31 (32%)	79 (32%)
≥2	31 (31%)	165 (39%)		33 (43%)	37 (38%)	95 (38%)